利拉鲁肽(Aulbio)(Liraglutide(Aulbio)) - 药物靶点：GLP-1R_在研适应症：糖尿病_专利_临床

概要

基本信息

药物类型

合成多肽

别名

AUL002-D、AUL002-O

靶点

GLP-1R

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

糖尿病

非在研适应症-

原研机构

Aulbio Co., Ltd.初创企业

在研机构

Aulbio Co., Ltd.初创企业

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

6

项与利拉鲁肽(Aulbio) 相关的临床试验

IRCT20240311061259N2

/ Recruiting临床3期IIT

Intragastric botulinum toxin injection with or without Liraglutide: A randomized controlled trial on the efficacy of an endoscopic bariatric therapy in combination with or without a glucagon-like peptide-1 receptor agonist on the rate of weight loss in overweight and obese patients

开始日期2024-11-05

申办/合作机构

Shahid Beheshti University of Medical Sciences

CTRI/2022/12/048456

/ CompletedN/A

An open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,cross-over, bioequivalence study of Liraglutide 0.6 mg Injection (6 mg/mL) (Test) of VirchowBiotech Private Limited, India and VictozaÂ® (Liraglutide) injection in pre-filled pen 0.6 mg (6 mg/mL) of Novo Nordisk A/S Novo AllÃ© DK-2880 BagsvÃ¦rd, Denmark in normal, healthy adult,human subjects under fasting conditions. - Nil

开始日期2022-12-26

申办/合作机构

Virchow Biotech Pvt Ltd.

CTRI/2020/07/026753

/ Completed临床1期

An open label, balanced, randomized, two treatment, two period, two-way crossover study to compare the single & multiple dose (steady state) pharmacokinetics profile of Biosimilar Liraglutide injection with VictozaÂ® in healthy adult, human subjects.

开始日期2020-07-14

申办/合作机构

Levim Biotech LLP

100 项与利拉鲁肽(Aulbio) 相关的临床结果

登录后查看更多信息

100 项与利拉鲁肽(Aulbio) 相关的转化医学

登录后查看更多信息

100 项与利拉鲁肽(Aulbio) 相关的专利（医药）

登录后查看更多信息

100 项与利拉鲁肽(Aulbio) 相关的药物交易

登录后查看更多信息